CA2438376A1 - Procede et dispositif de production d'antigenes et utilisation de ceux-ci - Google Patents

Procede et dispositif de production d'antigenes et utilisation de ceux-ci Download PDF

Info

Publication number
CA2438376A1
CA2438376A1 CA002438376A CA2438376A CA2438376A1 CA 2438376 A1 CA2438376 A1 CA 2438376A1 CA 002438376 A CA002438376 A CA 002438376A CA 2438376 A CA2438376 A CA 2438376A CA 2438376 A1 CA2438376 A1 CA 2438376A1
Authority
CA
Canada
Prior art keywords
class
mhc
molecules
peptide
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438376A
Other languages
English (en)
Inventor
William H. Hildebrand
Kiley Rae Prilliman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/974,366 external-priority patent/US7541429B2/en
Application filed by Individual filed Critical Individual
Publication of CA2438376A1 publication Critical patent/CA2438376A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de manière générale au moins un procédé et un dispositif de production d'antigènes solubles du CMH, et plus particulièrement, mais pas exclusivement, un procédé et un dispositif de production de molécules solubles des classes I et II du système HLA. L'invention comprend aussi les molécules des classes I et II du système HLA ainsi produites et leur utilisation. Selon les procédés de l'invention, les molécules des classes I et II du système HLA peuvent être produites à partir de matière première d'ADNg (ADN génomique) ou d'ADNc.
CA002438376A 2000-12-18 2001-12-18 Procede et dispositif de production d'antigenes et utilisation de ceux-ci Abandoned CA2438376A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25640900P 2000-12-18 2000-12-18
US25641000P 2000-12-18 2000-12-18
US60/256,409 2000-12-18
US60/256,410 2000-12-18
US09/974,366 US7541429B2 (en) 2000-10-10 2001-10-10 Comparative ligand mapping from MHC positive cells
US09/974,366 2001-10-10
PCT/US2001/049744 WO2002062846A2 (fr) 1999-12-17 2001-12-18 Procede et dispositif de production d'antigenes et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
CA2438376A1 true CA2438376A1 (fr) 2002-08-15

Family

ID=28678886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438376A Abandoned CA2438376A1 (fr) 2000-12-18 2001-12-18 Procede et dispositif de production d'antigenes et utilisation de ceux-ci

Country Status (4)

Country Link
EP (1) EP1353950A2 (fr)
CA (1) CA2438376A1 (fr)
IL (1) IL156473A0 (fr)
WO (1) WO2002062846A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001365A (en) * 1992-02-19 1999-12-14 The Scripps Research Institute In vitro activation of cytotoxic T cells
CA2175089A1 (fr) * 1993-10-25 1995-05-04 Eric T. Rhodes Expression procaryote de proteines du cmh
CA2263195A1 (fr) * 1996-08-16 1998-02-19 President And Fellows Of Harvard College Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees

Also Published As

Publication number Publication date
IL156473A0 (en) 2004-01-04
EP1353950A2 (fr) 2003-10-22
WO2002062846A2 (fr) 2002-08-15
WO2002062846A3 (fr) 2003-07-24

Similar Documents

Publication Publication Date Title
US20030166057A1 (en) Method and apparatus for the production of soluble MHC antigens and uses thereof
L Dudek et al. Epitope discovery and their use in peptide based vaccines
Mendoza et al. Minors Held by Majors: The H13Minor Histocompatibility Locus Defined as a Peptide/MHC Class I Complex
US20100003718A1 (en) Method and apparatus for the production of soluble mhc antigens and uses thereof
US8992937B2 (en) Disulfide trap MHC class I molecules and uses therefor
AU2018200222A1 (en) Engineering T-cell receptors
EP1704868A1 (fr) Peptides de liaison de HLA, et leurs utilisations
US20120302452A1 (en) Comparative ligand mapping from mhc class i positive cells
WO2014191432A1 (fr) Procédé amélioré pour la détection, la préparation et l'appauvrissement des lymphocytes t cd4+
Cao et al. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes.
Jackson et al. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer
Joshi et al. Flexibility in MHC and TCR recognition: degenerate specificity at the T cell level in the recognition of promiscuous Th epitopes exhibiting no primary sequence homology
EP1417487A2 (fr) Tests d'epitopes faisant appel au systeme hla
JPH11507354A (ja) 自己免疫疾患処置のためのｍｈｃクラスｉｉ分子のペプチドを用いるワクチン接種
US20060035338A1 (en) Method and apparatus for the production of soluble MHC antigens and uses thereof
Prilliman et al. Complexity among constituents of the HLA-B* 1501 peptide motif
CA2438376A1 (fr) Procede et dispositif de production d'antigenes et utilisation de ceux-ci
Class et al. Patent application title: METHOD AND APPARATUS FOR THE PRODUCTION OF SOLUBLE MHC ANTIGENS AND USES THEREOF Inventors: William H. Hildebrand (Edmond, OK, US) William H. Hildebrand (Edmond, OK, US) Kiley R. Prilliman (San Diego, CA, US)
Smith et al. Polymorphism at position 97 in MHC class I molecules affects peptide specificity, cell surface stability, and affinity for β2-microglobulin
US20090023630A1 (en) Methods and Means for Use in Diagnostics and Treatment of Diabetes
WO2007053644A2 (fr) Cartographie comparative des ligands de cellules positives vis-a-vis du mhc de classe i
Chaves et al. Replacement of the membrane proximal region of I-Ad MHC class II molecule with IE-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity
EP1625151A2 (fr) Representation cartographique comparative de ligands a partir de cellules positives de classe i du cmh
Fan et al. Recognition of a sequestered self peptide by influenza virus-specific CD8+ cytolytic T lymphocytes
Frankenberry Critical features of antigen-specific and allospecific recognition by cytotoxic T lymphocytes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130912